These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
119 related articles for article (PubMed ID: 11974529)
1. [Anti thyroglobulin antibodies in the follow up of patients with differentiated thyroid cancer: residual or relapsing disease markers?]. Quevedo I; Campino C; Rodríguez Portales JA; Arteaga E; López JM; Campusano C; González G; Fardella C; Slater J; Valdivia L; Poggi H; Foradori A; Velasco S Rev Med Chil; 2002 Feb; 130(2):167-72. PubMed ID: 11974529 [TBL] [Abstract][Full Text] [Related]
2. [Thyroglobulin: usefulness and limits in monitoring patients with thyroid carcinoma]. Hammami H; Sellem A; Ben Sellem D; Aouni Z; Elabri SB; Mezigh C; Machghoul S; Ben Brahim H Tunis Med; 2007 Feb; 85(2):128-30. PubMed ID: 17665659 [TBL] [Abstract][Full Text] [Related]
3. Effectiveness of peripheral thyrotropin receptor mRNA in follow-up of differentiated thyroid cancer. Milas M; Barbosa GF; Mitchell J; Berber E; Siperstein A; Gupta M Ann Surg Oncol; 2009 Feb; 16(2):473-80. PubMed ID: 19015922 [TBL] [Abstract][Full Text] [Related]
4. Frequency and clinical importance of anti-Tg auto-antibodies (ATG). Adil A; Jafri RA; Waqar A; Abbasi SA; Matiul-Haq ; Asghar AH; Jilani A; Naz I J Coll Physicians Surg Pak; 2003 Sep; 13(9):504-6. PubMed ID: 12971869 [TBL] [Abstract][Full Text] [Related]
5. [Recovery test or immunoradiometric measurement of anti-thyroglobulin autoantibodies for interpretation of thyroglobulin determination in the follow-up of different thyroid carcinoma]. Zöphel K; Wunderlich G; Liepach U; Koch R; Bredow J; Franke WG Nuklearmedizin; 2001 Oct; 40(5):155-63. PubMed ID: 11727628 [TBL] [Abstract][Full Text] [Related]
7. Circulating thyroglobulin mRNA does not predict early and midterm recurrences in patients undergoing thyroidectomy for cancer. Lombardi CP; Bossola M; Princi P; Boscherini M; La Torre G; Raffaelli M; Traini E; Salvatori M; Pontecorvi A; Bellantone R Am J Surg; 2008 Sep; 196(3):326-32. PubMed ID: 18614150 [TBL] [Abstract][Full Text] [Related]
8. [Clinical significance of serum thyroglobulin and antithyroglobulin antibody in differentiated thyroid cancer after thyroid ablation]. Vincze B; Sinkovics I; Keresztes S; Gergye M; Boér A; Remenár E; Péter I; Szentirmay Z; Kremmer T; Kásler M Magy Onkol; 2004; 48(1):27-34. PubMed ID: 15105893 [TBL] [Abstract][Full Text] [Related]
10. The additive clinical value of combined thyroglobulin and antithyroglobulin antibody measurements to define persistent and recurrent disease in patients with differentiated thyroid cancer. Aras G; Gültekin SS; Küçük NO Nucl Med Commun; 2008 Oct; 29(10):880-4. PubMed ID: 18769305 [TBL] [Abstract][Full Text] [Related]
11. Preoperative undetectable serum thyroglobulin in differentiated thyroid carcinoma: incidence, causes and management strategy. Giovanella L; Ceriani L; Ghelfo A; Maffioli M; Keller F Clin Endocrinol (Oxf); 2007 Oct; 67(4):547-51. PubMed ID: 17561976 [TBL] [Abstract][Full Text] [Related]
12. Evaluation of the diagnostic value of the first thyroglobulin determination in detecting metastases after differentiated thyroid carcinoma surgery. Makarewicz J; Adamczewski Z; Knapska-Kucharska M; Lewiński A Exp Clin Endocrinol Diabetes; 2006 Oct; 114(9):485-9. PubMed ID: 17115345 [TBL] [Abstract][Full Text] [Related]
13. Follow-up of differentiated thyroid carcinoma. Pagano L; Klain M; Pulcrano M; Angellotti G; Pasano F; Salvatore M; Lombardi G; Biondi B Minerva Endocrinol; 2004 Dec; 29(4):161-74. PubMed ID: 15765026 [TBL] [Abstract][Full Text] [Related]
14. Serum thyroglobulin concentrations predict disease-free remission and death in differentiated thyroid carcinoma. Heemstra KA; Liu YY; Stokkel M; Kievit J; Corssmit E; Pereira AM; Romijn JA; Smit JW Clin Endocrinol (Oxf); 2007 Jan; 66(1):58-64. PubMed ID: 17201802 [TBL] [Abstract][Full Text] [Related]
15. Predictive value of serum thyroglobulin after surgery for thyroid carcinoma. Hall FT; Beasley NJ; Eski SJ; Witterick IJ; Walfish PG; Freeman JL Laryngoscope; 2003 Jan; 113(1):77-81. PubMed ID: 12514386 [TBL] [Abstract][Full Text] [Related]
17. [Clinical validity of anti-thyroperoxidase antibody and anti-thyroglobulin antibody]. Lian XL; Bai Y; Sun ML; Guo ZS; Dai WX Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2004 Dec; 26(6):677-81. PubMed ID: 15663231 [TBL] [Abstract][Full Text] [Related]
18. Recombinant human thyroid-stimulating hormone (Thyrogen) in thyroid cancer follow up: experience at a single institution. Wong R; Topliss DJ; Bach LA; Hamblin PS; Kalff V; Long F; Stockigt JR Intern Med J; 2009 Mar; 39(3):156-63. PubMed ID: 19383064 [TBL] [Abstract][Full Text] [Related]
19. Therapeutic outcomes of papillary thyroid carcinomas with tumors more advanced than T1N0M0. Lin JD; Lin KJ; Chao TC; Hseuh C; Tsang NM Radiother Oncol; 2008 Oct; 89(1):97-104. PubMed ID: 18534700 [TBL] [Abstract][Full Text] [Related]
20. Management and outcome of recurrent well-differentiated thyroid carcinoma. Palme CE; Waseem Z; Raza SN; Eski S; Walfish P; Freeman JL Arch Otolaryngol Head Neck Surg; 2004 Jul; 130(7):819-24. PubMed ID: 15262757 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]